NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 242)
Posted On: 03/13/2018 7:14:39 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Results from Skin Absorption Study
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said that it has completed the first study evaluating DehydraTECH™ used in a topical cream formulation for absorption of cannabidiol (“CBD”) through human skin. Compared to control formulations, significant increases in the speed and quantity of CBD absorption through skin were proven in the study. Several factors were measured during the study at multiple testing intervals over a 48-hour duration, including the time required to detect CBD skin penetration and quantity as well as the peak amounts of CBD absorbed. Lexaria’s DehydraTECH-enabled topical formulation without the addition of either of the commercial penetration enhancers, demonstrated the highest overall average quantity of CBD delivered through the skin. Based on the positive results of the study, Lexaria intends to begin discussing potential additional commercial applications for its DehydraTECH technology with interested third parties from the topical products sector. “This first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications where delivery into the human circulatory system is required,” Lexaria Bioscience president John Docherty stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said that it has completed the first study evaluating DehydraTECH™ used in a topical cream formulation for absorption of cannabidiol (“CBD”) through human skin. Compared to control formulations, significant increases in the speed and quantity of CBD absorption through skin were proven in the study. Several factors were measured during the study at multiple testing intervals over a 48-hour duration, including the time required to detect CBD skin penetration and quantity as well as the peak amounts of CBD absorbed. Lexaria’s DehydraTECH-enabled topical formulation without the addition of either of the commercial penetration enhancers, demonstrated the highest overall average quantity of CBD delivered through the skin. Based on the positive results of the study, Lexaria intends to begin discussing potential additional commercial applications for its DehydraTECH technology with interested third parties from the topical products sector. “This first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications where delivery into the human circulatory system is required,” Lexaria Bioscience president John Docherty stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼